Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News bluebird bio Inc BLUE

Healthcare Biotechnology
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new... see more

Recent & Breaking News (NDAQ:BLUE)

bluebird bio Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Operational Progress

Business Wire February 18, 2020

bluebird bio Announces Upcoming Investor Events

Business Wire February 5, 2020

bluebird bio Announces Launch in Germany of ZYNTEGLO(TM) (autologous CD34+ cells encoding ?A-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent ?-Thalassemia Who Do Not Have ?0/?0 Genotype

Business Wire January 13, 2020

bluebird bio Announces Investor Events in January

Business Wire December 19, 2019

bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and Exposition

Business Wire December 9, 2019

bluebird bio Presents New Data Demonstrating Long-Term Transfusion Independence and Safety for LentiGlobin(TM) Gene Therapy for ?-thalassemia (betibeglogene autotemcel) at 61st ASH Annual Meeting and Exposition

Business Wire December 9, 2019

bluebird bio Announces Live Webcast to Review Clinical Data Presented at the American Society of Hematology (ASH) Annual Meeting

Business Wire December 2, 2019

bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy

Business Wire November 12, 2019

bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress

Business Wire October 31, 2019

bluebird bio Announces Transition of Chief Strategy Officer Jeffrey T. Walsh

Business Wire October 23, 2019

European Medicines Agency Approves Refined Commercial Manufacturing Specifications for ZYNTEGLO(TM)

Business Wire October 22, 2019

bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases

Business Wire October 9, 2019

bluebird bio Appoints William R. Sellers, M.D. to Board of Directors

Business Wire September 27, 2019

bluebird bio Presents Updated Data from Phase 2/3 Clinical Study of Lenti-D(TM) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

Business Wire September 18, 2019

bluebird bio to Present Data from Clinical Development Program of Lenti-DTM Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress

Business Wire September 3, 2019

bluebird bio Announces Investor Events in September

Business Wire August 22, 2019

bluebird bio Reports Second Quarter 2019 Financial Results and Highlights Operational Progress

Business Wire August 1, 2019

bluebird bio Presents New Data for LentiGlobin® Gene Therapy for Sickle Cell Disease (SCD) at 24th European Hematology Association (EHA) Congress

Business Wire June 14, 2019

bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent ?-Thalassemia (TDT) at 24th European Hematology Association (EHA) Congress

Business Wire June 14, 2019

bluebird bio Announces Live Webcast of EHA Data Review and ZYNTEGLO® (autologous CD34+ cells encoding ?A-T87Q-globin gene) Approval

Business Wire June 6, 2019